This website is for Israeli Healthcare Professionals only.

 

Product Information

Ozurdex - Intravitreal implant in applicator. One biodegradable implant contains 700 micrograms of dexamethasone in disposable injection device1.
Ozurdex targets multiple pathways in the complex and multifactorial DME pathogenesis3.

OZURDEX is indicated for the treatment of adult patients with1-2:

  • Diabetic macular oedema (DME) . Reimbursed by NHB in 2nd line after failure of 4 Avastin
  • Macular oedema following either BRVO or CRVO . Reimbursed by NHB: 1st line for special population* and in 2nd line after failure of 3 Avastin for pseudophakic patients.
    2nd linefor pakic patients is covered by suppementrtu
  • Inflammation of the posterior segment of the eye presenting as non-infectious uveitis. Reimbursed by NHB in 1st line
     

An image is for illustrative purposes only

Ozurdex Indications and Coverage

BRVO- branch retinal vein occlusion ; CRVO- central retinal vein occlusion ; TIA- transient ischemic attack

1. OZURDEX is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus. Ozurdex prescribing information. Nov2019

2. OZURDEX is not recommended during breast feeding unless clearly necessary. Ozurdex prescribing information. Nov2019

* Bevacizumab is not licensed for ophthalmic use. Allergan does not endorse unlicensed use of any product.

^For full information please refer to the ministry of health (MOH) circular for the national health basket expansion 2021.

Refrences:

  1. Ozurdex - Prescribing Information 
  2. National health basket expansion 2021
  3. Zur D, et al. Ophthalmic Res. 2019;62:231–236

IL-OZU-230034